Efficacy and safety of PF299804 versus erlotinib (E): A global, randomized phase II trial in patients (pts) with advanced non-small cell lung cancer (NSCLC) after …

MJ Boyer, FH Blackhall, K Park, CH Barrios… - Journal of Clinical …, 2010 - ascopubs.org
LBA7523 Background: PF299804, a potent, irreversible inhibitor of human epidermal growth
factor receptor (HER)-1/EGFR,-2, and-4 tyrosine kinases (TK), is active in E-sensitive and …
被引用次数：66 相关文章

[引用][C] Efficacy and safety of PF299804 versus erlotinib (E): A global, randomized phase II trial in patients (pts) with advanced non-small cell lung cancer (NSCLC) after …

MJ Boyer, FH Blackhall, K Park… - JOURNAL OF …, 2010 - scholarworks.bwise.kr
ScholarWorks@SUNGKYUNKWAN UNIVERSITY: Efficacy and safety of PF299804 versus
erlotinib (E): A global, randomized phase II trial in patients (pts) with advanced non-small cell …